New therapy for specific form of leukemia
Leukemia, or cancer of the bone marrow, strikes some 700 Belgians each year. Medical science has been at a total loss regarding the origin or cause of some forms of this disease − including T-cell acute lymphatic leukemia, or T-ALL. But now, researchers from the Flanders Interuniversity Institute for Biotechnology (VIB), connected to the Catholic University of Leuven, have discovered the possible cause of the disease in 6% of the T-ALL patients. The scientists have found small circular DNA fragments in the cells of these patients that contain the ABL1 cancer gene. ABL1 also plays an important role in other forms of leukemia. The good news is that ABL1 is counteracted with the drug Glivec, and so this medication can now also provide help to a number of T-ALL patients.
T-ALL: T-cell acute lymphatic leukemia In normal circumstances, our white blood cells combat foreign intruders, like viruses and bacteria. However, in leukemia, there is a breakdown in the formation of white blood cells. The cells in the bone marrow that should develop into white blood cells multiply out of control without fully reaching maturity. These blood cells function inadequately, disrupting the production of normal blood cells. Among other effects, this makes patients more susceptible to infections. Leukemia appears in several forms − in the case of T-ALL, a large accumulation of immature white blood cells occurs within a very short time. This is the most common type of cancer in children under the age of 14 − striking children between two and three years of age, in particular. At present, an optimal treatment, with chemotherapy, cures over half of these children.
ABL1 plays a prominent role in several forms of leukemia
ABL1 is a kinase, a type of protein that catalyzes a number of processes in the cell − in the case of ABL1, this is the process of cell division. It is crucial that kinases function in a very controlled manner within our cells. Loss of control of their functioning disturbs the normal functioning and division of cells. Thus, such disorders in the functioning of ABL1 are a major cause of certain forms of leukemia. Existing drug now used with T-ALL patients Research performed by Jan Cools and his colleagues, under the direction of Peter Marynen, shows for the first time that ABL1 also lies at the root of T-ALL − which has a direct effect on the treatment of T-ALL patients. Indeed, a drug exists − called Glivec − that suppresses the action of ABL1. Glivec has already been successfully administered to patients with other forms of leukemia in which ABL1 plays a role. The new research results show that Glivec can also provide a better treatment for a small group of T-ALL patients. Jan Cools has already successfully conducted the first laboratory tests with Glivec on the cancer cells of these patients.
The team of Jan Cools and Peter Marynen, along with Carlos Graux and colleagues from the Centre for Human Heredity under the direction of Anne Hagemeijer, noticed that the ABL1 gene was present in greater quantities in the white blood cells of 6% of the T-ALL patients. The genetic code of ABL1 is at chromosome 9. Through a flaw at the ABL1 gene, a piece of DNA is split off and ’takes on a life of its own’ as it were. This fragment contains the ABL1 gene, connected to another gene. Due to this fusion, ABL1 works non-stop − stimulating cell growth unremittingly. This process leads to an uncontrolled growth of immature white blood cells and thus to T-ALL. With these findings, the researchers have revealed a new mechanism for the formation of active cancer genes on circular DNA fragments. The researchers are now concentrating their efforts on discovering the role of ABL1 and other kinases in all T-ALL patients. In the future, they hope to be able to administer Glivec, and other kinase inhibitors, to treat these patients as well.
Relevant scientific publications
The research of the VIB scientists from Peter Marynen’s group appears on 1 October in the authoritative journal, Nature Genetics (Graux C, Cools J et al., Nature Genetics, 36(10):1084-1089 (2004)) and is online on the journal’s website: http://www.nature.com/naturegenetics.
Sooike Stoops | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...